Kornimate/medical-research-clean huggingface dataset:
480 biomedical sinus drug depot

Conditions: Chronic Sinusitis

Summary: this is a phase i, exploratory safety study of the 480 biomedical mometasone furoate sinus drug depot in adult subjects with chronic sinusitis.


Eligibility criteria:
inclusion criteria: * diagnosis of cs. * female study subjects of child-bearing potential must have a negative pregnancy test and must agree to not become pregnant during the course of the study. * the study subject has been informed of the nature of the study, agrees to its provisions and has provided written informed consent as approved by the ethics committee of the respective clinical site. * the study subject agrees to comply with all study requirements exclusion criteria: * known history of intolerance to corticosteroids. * oral-steroid dependent condition. * having had corticosteroids with potential systemic effect (e.g., oral, parenteral, or high dose topical) 1 month prior to screening visit. * subjects with acute or chronic intracranial or orbital complications of chronic rhinosinusitis (e.g., brain abscess, related problems with eyes or central nervous system). * known history of hypothalamic pituitary adrenal (hpa) axial dysfunction or having morning serum cortisol level at screening outside of normal range. * previous pituitary or adrenal surgery. * history or diagnosis (in either eye) of glaucoma, ocular hypertension, or cataracts. * recent participation in another clinical trial within 1 month of screening visit. * subjects currently participating in an investigational drug or device study.
myogene: effects of acute exercise on (myokine) gene expression in human skeletal muscle

Conditions: Exercise; Muscle; Gene Expression; Myokine

Summary: rationale: proteins released from muscle during and shortly after exercise, often referred to as myokines, may be central to our understanding of the cross-talk during and after exercise between skeletal muscles and other organs, in particular the liver. so far only a few myokines are identified (e.g. il-6, il-8, il-15, tnf-alpha). taking into account the role of these several known myokines in developing insulin resistance, revealing new putative myokines might provide valuable information and a direction for future research on the pathogenesis and treatment of type 2 diabetes mellitus. objective: the objective of the present study is to identify novel myokines, expression of which is altered in skeletal muscle after a single bout of exercise. study design: experimental study. study population: ten healthy, male subjects between 40 and 60 years of age and bmi \< 30 kg/m2, will participate in this study. intervention: a single exercise bout that consists of one hour one-legged cycling on a adapted recumbent cycle ergometer at a submaximal rate. the non-exercising leg will serve as control for the exercising leg. main study outcomes: main study outcomes include upregulation of genes in skeletal muscle after exercise (with a focus on genes encoding myokines) and changes of blood plasma levels of selected proteins after exercise.


Eligibility criteria:
inclusion criteria: * age 40-60 years * male gender * bmi \< 30 kg/m2 exclusion criteria: * exercising regularly (\> 2 times a week, \> 3 hour in total per week) * unstable body weight (weight gain or loss \> 3 kg in the past three months) * following, or have recently followed a (weight-loss) diet * donated or intended to donate blood 2 months before until two months after the study * medical condition that can interfere with the study outcome (i.e. cardiovascular disease, pulmonary disease) * systolic blood pressure \>160 mmhg and/or diastolic blood pressure \>100 mmhg * use of medications known to interfere with gene expression in the muscles (i.e. statins, fenofibrate). * use of antithrombotic therapy (marcoumar, sintromitis). * diagnosed diabetes mellitus type 1 or 2. * drugs or alcohol abuse ( \> 3 glasses of alcoholic beverages a day). * (chronic) injuries of the locomotor system that can interfere with the intervention * participated in another study within the last six months
enhanced recovery program after laparoscopic colon cancer surgery

Conditions: Colon Cancer

Summary: an enhanced recovery program has been developed to provide for colon cancer patients faster and more personalized postoperative treatment. most of the previous studies have showed that the efficacy of the enhanced recovery program on both subjective and objective physical recovery of patients. however, such studies are rarely conducted in south korea. the purpose of this study is to evaluate the feasibility and efficacy of a postoperative enhanced recovery program in patients who underwent laparoscopic colon cancer surgery at a tertiary hospital in korea.


Eligibility criteria:
inclusion criteria: * eligibility rule of enrollment * ecog 0-2 * pathologically diagnosed colon cancer * stage i-iii * no functional disturbance in liver, kidney, bone marrow * informed consent exclusion criteria: * emergent operation * obstructive or perforated cancer * rectosigmoid or rectal cancer * synchronous tumor * uncontrolled psychiatric or neurologic problems * severe hepatic dysfunction (got, gpt ≥100iu/l) * renal dysfunction (cr ≥2mg/dl) * recent mi, cva, nitrate medication

Keywords: perioperative treatment laparoscopic surgery
post marketing surveillance of nintedanib in indian patients with idiopathic pulmonary fibrosis

Conditions: Idiopathic Pulmonary Fibrosis

Summary: this is an active surveillance study to monitor the real world safety of nintedanib in indian patients with idiopathic pulmonary fibrosis. the safety of nintedanib has been assessed in clinical trials.this active surveillance aims to collect the safety data of 200 ipf patients treated with nintedanib in approved indication after the commercial availability of the drug in india (23rd january 2017). the objective is to look at safety of nintedanib in the real world setting.


Eligibility criteria:
inclusion criteria: * patients with documented diagnosis of idiopathic pulmonary fibrosis (ipf) based upon ats/ers/jrs/alat 2011 guidelines (nintedanib naïve or pirfenidone pre-treated) who have initiated or will initiate nintedanib according to the package insert after the commercial availability of drug in india (23rd january 2017). * patients in whom it is possible to obtain voluntary informed consent either from the patient or patient's legally authorised representative (applicable for group b and c patients). * patients in whom data collection is possible from the medical records (applicable for group a and b patients) * further inclusion criteria apply exclusion criteria: * patients who were previously treated with nintedanib. * patients who have initiated or will initiate nintedanib concomitantly with pirfenidone.. * patients who are participating in a clinical trial. * further exclusion criteria apply.
the difference between rehabilitation with or without strength training after total knee replacement

Conditions: Osteoarthritis, Knee

Summary: background and purpose: in the early phase after a total knee replacement (tka), patients experience a decrease in leg muscle strength with up to about 80%. this considerable loss of muscle strength is related to reduced functional performance at this point in time. as the loss of muscle strength and functional performance is most pronounced early after tka, rehabilitation including strength training initiated early after tka seems a logical choice. however, tradition and fear of symptom exacerbation, such as increased knee joint swelling, knee pain and slow recovery of knee joint range of motion, have typically precluded strength training early after tka. hypothesis: our hypothesis is that the effect of early rehabilitation including strength training will be greater than rehabilitation without strength training. if the hypothesis is confirmed, strength training early after tka could be implemented directly into clinical rehabilitation practice. participants and methods: seventy participants with a unilateral tka, between the age of 18 to 80 years, who understand and speak danish, have given informed consent, will be included in this study.the study is a single-blinded randomized controlled study, where the participants receive supervised 1) rehabilitation with or 2) rehabilitation without strength training in 7 weeks. all components of the rehabilitation program (balance-, and mobility training etc.) are the same in both groups except the strength training exercises. instead of the strength training exercises, the group without strength training spend more time on warm-up exercises, mobility- and balance exercises. the rehabilitation program lasts 1 hour per session, and will be performed twice per week. the participants perform a test battery 4 times from before to 6 months after the tka. the test battery assesses the participants' walking ability, leg strength, knee pain, knee joint swelling- and range of motion, and self-reported function and quality of life. ethical issues: from a pilot study conducted in the beginning of 2010, the investigators found, that strength training initiated early after tka seems feasible, and does not increase knee joint swelling and knee pain. none of the financial supporters, or any of the authors, have any potential conflicts of interest with regard to the study.


Eligibility criteria:
inclusion criteria: * participants with a primary unilateral total knee arthroplasty. * age between 18 and 80 years. * participants must understand and speak danish. * participants undergo surgery at copenhagen university hospital, hvidovre, and live in the counties of copenhagen, brøndby or hvidovre. exclusion criteria: * disease/musculoskeletal disorder, which requires special rehabilitation modality. * alcohol and drug abuse. * lack of wish to participate or unwillingness to sign an informed consent.

Keywords: arthroplasty, replacement, knee resistance training physical therapy modalities randomized controlled trial
study of recombinant adenovirus advince in patients with neuroendocrine tumors; safety and efficacy

Conditions: Neuroendocrine Tumors

Summary: an open-labelled, uncontrolled, single-center phase i/iia clinical study to evaluate the safety of repeated infusions of advince into the hepatic artery in patients with metastatic neuroendocrine tumors (nets), and if possible determination of maximum tolerated dose.

an open-labelled, uncontrolled, single-center phase i/iia clinical study to evaluate the safety of repeated infusions of advince into the hepatic artery in patients with metastatic neuroendocrine tumors (nets), and if possible determination of maximum tolerated dose. secondary objectives include to evaluate the anti-tumoral efficacy of advince infusions on metastatic neuroendocrine tumors, to determine the replication profile of advince and to determine the humoral (antibody) and cytokine-mediated immune response to advince. minimum 12 and maximum 35 patients will be included, the number is based on the toxicity observed.

Eligibility criteria:
inclusion criteria: 1. subject´s written informed consent 2. histologically and radiologically confirmed progressive neuroendocrine carcinoma of gastrointestinal, pancreatic or bronchial origin with multiple liver metastases. progression in clinical symptoms and tumor growth verified over the last 6 months on ct or mri 3. cancer that is not considered resectable for potential cure or tumor reduction 4. patent portal vein and adequate liver perfusion 5. liver dominant disease with involvement of \<60% of liver parenchyma 6. karnofsky performance status of \>=70% 7. life expectancy of \>=6 months 8. \>=18 years of age 9. must use a reliable method of contraception if sexually active and of reproductive potential 10. plasma creatinine \<105 ug/ml 11. aspartate transaminase (ast), alanine transaminase (alt) and alkaline phosphatase (alp) \<3.0-fold upper limit of normal 12. total bilirubin \<2.0-fold upper limit of normal 13. prothrombin time (pt)/international normalized ratio (inr) \<2.0 and prothromboplastin time (ptt) within normal limits 14. neutrophils \>1500/ml, hemoglobin \>100 g/l, platelets \>100 000/ml 15. patients with functioning net should have cover by somatostatin analog exclusion criteria: 1. known chronic liver dysfunction before the development of metastatic cancer (e.g. cirrhosis, chronic hepatitis) 2. active infection, including documented hiv and hepatitis c 3. any viral syndrome diagnosed within the previous 2 weeks 4. chemotherapy within the previous 4 weeks before the first treatment 5. radiotherapy to the target tumor site within the last 24 weeks from the baseline ct scan 6. concomitant malignancy 7. pregnant or lactating females 8. prior participation in any research protocol that involved administration of adenovirus vectors 9. treatment with any other investigational therapy within the last 4 weeks, organ transplantation prior to treatment, severe cardiovascular, metabolic or pulmonary disease 10. continuing treatment with any other cancer therapy
effects of menthol gum chewıng on postoperatıve nausea, vomiting, and length of hospital stay in children undergoing appendectomy: a randomızed controlled trıal

Conditions: Postoperative Nausea and Vomiting; Hospitalism in Children

Summary: the study was conducted as an experimental study to determine the effect of menthol chewing gum application on postoperative nausea, vomiting and hospital stay in children with appendectomy. the population of the study consisted of children aged 7-18 who underwent appendectomy in bursa yüksek i̇htisas training and research hospital pediatric surgery clinic between april and june 2022. in the sample of the study, a total of 60 children (menthol gum group- intervention group=30, control=30) who had postoperative nausea-vomiting, accepted to participate in the study and met the sample selection criteria were included. starting from the second hour after the child was brought to the clinic after appendectomy, the children in the chewing gum group with nausea and vomiting were chewed gum for an average of 15 minutes. the patients in the study group were not intervened except for routine nursing care. during the chewing gum (between 5-10. minutes), up to 30., 60. and 120. minutes after the chewing gum.the patient was re-evaluated in terms of nausea with the barf nausea scale. episodes of vomiting were recorded in patients with vomiting. after the quantitative stages of the study were completed, the patient's level of relief was evaluated using a verbal descriptive scale. nausea and vomiting were also evaluated before the patient was discharged.


Eligibility criteria:
inclusion criteria: * child and parent's willingness to participate in the research * the child has no intellectual disability or perception problems. * patients who underwent general anesthesia * patients who do not develop postoperative complications * patients in the 7-18 age group * patients who can tolerate chewing gum in the postoperative period * patients who like to chew gum * patients with nausea and vomiting exclusion criteria: * patients with a diagnosis of diabetes * patients with teeth and jaw problems * patients with menthol allergy * patients with irritable bowel syndrome * patients with a history of reflux * patients whose cognitive level is not suitable * patients with a nasogastric tube

Keywords: child appendectomy nausea and vomiting chewing gum length of hospitalization
jak inhibition in food allergy

Conditions: Food Allergy

Summary: this study will assess the role for an oral targeted medication, abrocitinib, as a new treatment option for food allergy patients that would avoid injections. abrocitinib, which has successfully completed phase three trials for atopic dermatitis, could serve as a single therapy for two conditions in many patients with multiple atopic conditions.


Eligibility criteria:
inclusion criteria: * 18 - 50 years old * participant must be able to understand and perform informed consent. * ige-mediated food allergy to at least one of the following foods as defined by (regarding at least one of the foods): ° foods: peanut, cashew, walnut, hazelnut, sesame, cod, and/or shrimp, history of an acute allergic reaction (urticaria, angioedema, cough, wheeze, and/or repetitive vomiting within an hour of ingestion, and history of positive skin or serum ige test, and current strict avoidance of the food, and current possession of physician-prescribed self-injectable epinephrine, and skin test wheal 5 mm or greater average diameter * current or past eczema. * if female of childbearing potential, must have a negative pregnancy test (serum or urine) and agree to abstinence or acceptable contraception. * plan to remain in the tri-state area during the trial for visits. * must agree to avoid prolonged exposure to the sun and not to use tanning booths, sunlamps, or other ultraviolet (uv) light sources during the study. * if receiving concomitant medications for any reason other than ad, must be on a stable regimen, which is defined as not starting a new drug or changing dosage within 7 days or 5 half-lives (whichever is longer) prior to day 1 and through the duration of the study. exclusion criteria: * unwilling or unable to give written informed consent or comply with protocol. * unable to swallow pill. * use of dupilumab within 6 weeks of enrollment. * prior use or allergy to drugs related to abrocitinib (ruxolitinib, upadacitinib, etc). * use of any other biologic (monoclonal antibody) medication within 12 weeks or 5 half-lives of drug, if known. * allergy to any excipients within abrocitinib. * use of build-up environmental immunotherapy; any food oral immunotherapy;or systemic oral, iv or im steroids including but not limited to- prednisone, methylprednisolone, prednisolone, solumedrol, solucortef, dexamethasone in the past 4 weeks or 5 half-lives of drug, if known. * use of cyp2c9 and cyp2c19 inducers (such as carbamazepine, norfluoxetine, etc.) within 5 half-lives of the inducer plus 14 days prior to the first dose of study intervention. * use of cyp2c9 and cyp2c19 inhibitors within 1 week of first dose of study intervention or within 5 half-lives (if known) of the inhibitor, whichever is longer. * unable to stop long-acting antihistamines within minimum wash out period required for spts at screening and site visits * history of or significant risk factor(s) for cardiovascular disease

Keywords: food allergy jak jak inhibitor abrocitinib immunoglobulin e
stress balls in gynecologic exams: a patient comfort trial

Conditions: Gynecologic

Summary: women's anxiety about gynecological examinations causes them to skip examinations during this process. research shows that women with high levels of anxiety are more likely to feel pain. women who can manage their anxiety can increase their satisfaction by reducing pain levels during the examination . the stress ball has the potential to improve the patient experience by reducing these anxieties. this will positively affect women's willingness to participate in gynecological examinations and follow-up processes.


Eligibility criteria:
inclusion criteria: * being between the ages of 18-35, * being literate, knowing and understanding turkish, * don't have a pap-smear test for the first time, exclusion criteria: * presence of chronic pain in the pelvic region, * presence of a condition in the wrists that prevents squeezing the stress ball, * congenital malformation of the cervix, .having a known diagnosis of a serious psychiatric illness.

Keywords: pain women health pap-smear anxiety
comparing steroid injections and platelet rich plasma injections in the treatment of plantar fasciitis

Conditions: Plantar Fasciitis

Summary: in cases of plantar fasciitis not responding to conservative management, minimally invasive techniques may be used. these include platelet rich plasma injections and corticosteroid injections. corticosteroids have long been used for symptomatic relief. however there are growth factors present in prp injections that contribute to the healing of the pathology, and not just symptom control. a single blind, prospective, randomized, comparative, control study will be performed. the study population consists of a total of 80 participants. they will be randomly assigned to receive either a corticosteroid injection, or a platelet rich plasma injection. data will be collected through questionnaires and ultrasound findings. patients will have a follow up at 3, 6, 12, and 24 weeks after they receive their injection.


Eligibility criteria:
inclusion criteria: * patients aged 18+ * patients with plantar fasciitis for at least 6 months which has not responded to 6 weeks of conservative therapy * patients with a visual analogue score (vas) of more than 5 in the morning * patients must be able to understand the informed consent and have the ability to follow up. exclusion criteria: * patients who have had repeated corticosteroid injections within the past 3 months, or have taken a non-steroid anti inflammatory drug during the 1 week prior to receiving an intervention * bmi \> 40 * patients with a previous foot deformity * patients who have had previous foot surgery * history of anemia (hb \< 7) * confirmed diagnosis of neuropathy * patients who have the inability to follow up

Keywords: plantar fasciitis steroid platelet rich plasma injection ultrasound
the utility of cap colonoscopy in increasing adenoma detection rate

Conditions: Adenoma

Summary: this is a research study about the usefulness of transparent cap during screening colonoscopy. the purpose of the research is to test the usefulness of adding small cap to the tip of the colonoscope. the investigators hypothesis is that cap assisted colonoscopy will improve the detection of adenomatous polyps (polyps which can become colon cancer later on) in comparison to the standard colonoscopy.

this is a prospective, randomized trial comparing the adenoma detection rate between hispanic patients undergoing a screening colonoscopy with a conventional colonoscope or with a cap-assisted colonoscopy. the aims of the study are: 1. compare adr between hispanic patients undergoing a screening colonoscopy with and without cap. 2. compare the overall polyp detection rate between hispanic patients undergoing a screening colonoscopy with and without cap. 3. compare the cecal intubation rate and cecal intubation time between standard colonoscopy and cap assisted colonoscopy. 4. compare the complication rate between standard colonoscopy and cap assisted colonoscopy.

Eligibility criteria:
inclusion criteria: * adult hispanic patients (18-80) who are undergoing colonoscopy for screening or surveillance purposes. exclusion criteria: 1. patients younger than 18 yrs old or older than 80 yrs. 2. patients with a prior history of colonic surgeries 3. patient with crohns colitis or ulcerative colitis. 4. patient with prior history of colon cancer 5. patient with poor bowel preparation

Keywords: screening colonoscopy
prebiotics as a means to modulate gut fermentation, metabolism, appetite and cognition

Conditions: Metabolic Syndrome

Summary: this study aims at investigating the impact of colonic fermentation of intrinsic indigestible carbohydrates in cereal whole kernels after three days consumption, on metabolic variables and cognition. the study is performed in healthy, normal to slightly over-weight test subjects.


Eligibility criteria:
inclusion criteria: * bmi 19-28 kg/m2 exclusion criteria: * gastrointestinal diseases * metabolic disorders * tobacco/snuff user * antibiotic/probiotic treatment